Global Polio Vaccine Market Growth 2026-2032
The global Polio Vaccine market size is predicted to grow from US$ 1377 million in 2025 to US$ 1881 million in 2032; it is expected to grow at a CAGR of 4.4% from 2026 to 2032.
Polio vaccine is a preventive biological product used to prevent poliovirus infection and the risk of acute flaccid paralysis caused by poliomyelitis. It mainly includes injectable Inactivated Polio Vaccine, Oral Polio Vaccine, Sabin-strain Inactivated Polio Vaccine, and multivalent combination vaccines containing polio antigen components. By inducing active immunity against polioviruses, these products protect individuals while helping maintain population-level immune barriers, reduce transmission, and prevent importation risks. Based on technology route, IPV emphasizes safety and long-term protection in the post-eradication stage, OPV emphasizes intestinal mucosal immunity, rapid coverage, and transmission interruption, while combination vaccines improve pediatric vaccination convenience and immunization program efficiency. Polio vaccines combine public health necessity, national strategic reserve value, and high technical barriers, making them one of the most important vaccine categories in the global polio eradication agenda.In 2025, global Polio vaccine production reached approximately 785 million units.The average gross profit margin of this product is 70%.
The market opportunities for polio vaccines are driven by the final stage of global polio eradication, continuous upgrading of immunization programs, and rising vaccine safety requirements. As countries optimize the use structure of OPV and IPV, the polio vaccine market is no longer a single low-price public health category. Instead, it has formed a multilayer product system in which IPV strengthens the safety foundation, OPV interrupts transmission, combination vaccines improve vaccination experience, and novel OPV enhances emergency response. China?s current immunization strategy adopts a sequential schedule of IPV and bOPV, showing that policymakers value both the safety of inactivated vaccines and the herd-immunity role of oral vaccines. WHO prequalification of novel oral polio vaccines further strengthens the global emergency supply system. For manufacturers, polio vaccines represent a strategic product platform connected to national immunization programs, international organization procurement, domestic substitution, combination vaccine upgrading, and global public health cooperation.
The industry?s challenges are concentrated in policy transition, quality regulation, biosafety, and supply stability. OPV has strong transmission-interruption advantages, but because it contains live attenuated virus and carries vaccine-derived virus risks, its routine-use space will gradually adjust as global polio eradication progresses. IPV has a stronger safety profile, but its manufacturing process is more complex and cost-intensive, requiring high standards for cell culture, virus purification, inactivation validation, and antigen consistency. Combination vaccines involve even higher barriers, including multi-antigen compatibility, immune interference, adjuvant systems, and clinical validation. Because polio vaccines are administered to children and used in public health systems, regulators impose strict requirements on registration approval, GMP, batch release, cold-chain traceability, and post-marketing surveillance. Companies lacking stable capacity, international certification, and mature quality systems will find it difficult to build long-term advantages in government procurement and global supply systems.
Downstream demand is expanding from basic immunization to sequential vaccination, catch-up vaccination, emergency stockpiling, outbreak control, international aid, and premium combination vaccination. Disease control systems focus on whether product portfolios can balance safety, coverage efficiency, supply stability, and transmission interruption. Vaccination clinics require products with clear dosage forms, stable distribution, convenient operation, and easy parent communication. International organizations and developing-country markets place greater emphasis on accessibility, cold-chain adaptability, and emergency response speed. The self-pay market focuses more on fewer injections and greater convenience delivered by IPV-containing multivalent vaccines. In the future, demand for polio vaccines will no longer be driven only by birth cohorts, but also by global importation risks, immunization strategy adjustments, combination vaccine upgrading, and public health stockpile mechanisms.
LP Information, Inc. (LPI) ' newest research report, the ?Polio Vaccine Industry Forecast? looks at past sales and reviews total world Polio Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Polio Vaccine sales for 2026 through 2032. With Polio Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Polio Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Polio Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Polio Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Polio Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Polio Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Polio Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Polio Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Polio Vaccine market?
What factors are driving Polio Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Polio Vaccine market opportunities vary by end market size?
How does Polio Vaccine break out by Type, by Application?
Polio vaccine is a preventive biological product used to prevent poliovirus infection and the risk of acute flaccid paralysis caused by poliomyelitis. It mainly includes injectable Inactivated Polio Vaccine, Oral Polio Vaccine, Sabin-strain Inactivated Polio Vaccine, and multivalent combination vaccines containing polio antigen components. By inducing active immunity against polioviruses, these products protect individuals while helping maintain population-level immune barriers, reduce transmission, and prevent importation risks. Based on technology route, IPV emphasizes safety and long-term protection in the post-eradication stage, OPV emphasizes intestinal mucosal immunity, rapid coverage, and transmission interruption, while combination vaccines improve pediatric vaccination convenience and immunization program efficiency. Polio vaccines combine public health necessity, national strategic reserve value, and high technical barriers, making them one of the most important vaccine categories in the global polio eradication agenda.In 2025, global Polio vaccine production reached approximately 785 million units.The average gross profit margin of this product is 70%.
The market opportunities for polio vaccines are driven by the final stage of global polio eradication, continuous upgrading of immunization programs, and rising vaccine safety requirements. As countries optimize the use structure of OPV and IPV, the polio vaccine market is no longer a single low-price public health category. Instead, it has formed a multilayer product system in which IPV strengthens the safety foundation, OPV interrupts transmission, combination vaccines improve vaccination experience, and novel OPV enhances emergency response. China?s current immunization strategy adopts a sequential schedule of IPV and bOPV, showing that policymakers value both the safety of inactivated vaccines and the herd-immunity role of oral vaccines. WHO prequalification of novel oral polio vaccines further strengthens the global emergency supply system. For manufacturers, polio vaccines represent a strategic product platform connected to national immunization programs, international organization procurement, domestic substitution, combination vaccine upgrading, and global public health cooperation.
The industry?s challenges are concentrated in policy transition, quality regulation, biosafety, and supply stability. OPV has strong transmission-interruption advantages, but because it contains live attenuated virus and carries vaccine-derived virus risks, its routine-use space will gradually adjust as global polio eradication progresses. IPV has a stronger safety profile, but its manufacturing process is more complex and cost-intensive, requiring high standards for cell culture, virus purification, inactivation validation, and antigen consistency. Combination vaccines involve even higher barriers, including multi-antigen compatibility, immune interference, adjuvant systems, and clinical validation. Because polio vaccines are administered to children and used in public health systems, regulators impose strict requirements on registration approval, GMP, batch release, cold-chain traceability, and post-marketing surveillance. Companies lacking stable capacity, international certification, and mature quality systems will find it difficult to build long-term advantages in government procurement and global supply systems.
Downstream demand is expanding from basic immunization to sequential vaccination, catch-up vaccination, emergency stockpiling, outbreak control, international aid, and premium combination vaccination. Disease control systems focus on whether product portfolios can balance safety, coverage efficiency, supply stability, and transmission interruption. Vaccination clinics require products with clear dosage forms, stable distribution, convenient operation, and easy parent communication. International organizations and developing-country markets place greater emphasis on accessibility, cold-chain adaptability, and emergency response speed. The self-pay market focuses more on fewer injections and greater convenience delivered by IPV-containing multivalent vaccines. In the future, demand for polio vaccines will no longer be driven only by birth cohorts, but also by global importation risks, immunization strategy adjustments, combination vaccine upgrading, and public health stockpile mechanisms.
LP Information, Inc. (LPI) ' newest research report, the ?Polio Vaccine Industry Forecast? looks at past sales and reviews total world Polio Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Polio Vaccine sales for 2026 through 2032. With Polio Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Polio Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Polio Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Polio Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Polio Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Polio Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Polio Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Polio Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Inactivated Polio Vaccine (IPV)
- Oral Polio Vaccine (OPV)
- Monovalent
- Bivalent
- Trivalent
- Oral Drops
- Sugar Pill
- Injection
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- GSK
- Bibcol
- Serum Institute (Bilthoven Biologicals)
- Tiantan Biological
- IMBCA
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
What is the 10-year outlook for the global Polio Vaccine market?
What factors are driving Polio Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Polio Vaccine market opportunities vary by end market size?
How does Polio Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Polio Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Polio Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Polio Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Polio Vaccine Segment by Type
2.2.1 Inactivated Polio Vaccine (IPV)
2.2.2 Oral Polio Vaccine (OPV)
2.2.3 Polio Vaccine Sales by Type
2.2.3.1 Global Polio Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Polio Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Polio Vaccine Sale Price by Type (2021-2026)
2.3 Polio Vaccine Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Polio Vaccine Sales by Virus Type
2.3.4.1 Global Polio Vaccine Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Polio Vaccine Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Polio Vaccine Sale Price by Virus Type (2021-2026)
2.4 Polio Vaccine Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Injection
2.4.4 Polio Vaccine Sales by Dosage Form
2.4.4.1 Global Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
2.4.4.2 Global Polio Vaccine Revenue and Market Share by Dosage Form (2021-2026)
2.4.4.3 Global Polio Vaccine Sale Price by Dosage Form (2021-2026)
2.5 Polio Vaccine Segment by Application
2.5.1 Public
2.5.2 Private
2.5.3 Polio Vaccine Sales by Application
2.5.3.1 Global Polio Vaccine Sale Market Share by Application (2021-2026)
2.5.3.2 Global Polio Vaccine Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Polio Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Polio Vaccine Breakdown Data by Company
3.1.1 Global Polio Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Polio Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Polio Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Polio Vaccine Revenue by Company (2021-2026)
3.2.2 Global Polio Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Polio Vaccine Sale Price by Company
3.4 Key Manufacturers Polio Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Polio Vaccine Product Location Distribution
3.4.2 Players Polio Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR POLIO VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Polio Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Polio Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Polio Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Polio Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Polio Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Polio Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Polio Vaccine Sales Growth
4.4 APAC Polio Vaccine Sales Growth
4.5 Europe Polio Vaccine Sales Growth
4.6 Middle East & Africa Polio Vaccine Sales Growth
5 AMERICAS
5.1 Americas Polio Vaccine Sales by Country
5.1.1 Americas Polio Vaccine Sales by Country (2021-2026)
5.1.2 Americas Polio Vaccine Revenue by Country (2021-2026)
5.2 Americas Polio Vaccine Sales by Type (2021-2026)
5.3 Americas Polio Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Polio Vaccine Sales by Region
6.1.1 APAC Polio Vaccine Sales by Region (2021-2026)
6.1.2 APAC Polio Vaccine Revenue by Region (2021-2026)
6.2 APAC Polio Vaccine Sales by Type (2021-2026)
6.3 APAC Polio Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Polio Vaccine by Country
7.1.1 Europe Polio Vaccine Sales by Country (2021-2026)
7.1.2 Europe Polio Vaccine Revenue by Country (2021-2026)
7.2 Europe Polio Vaccine Sales by Type (2021-2026)
7.3 Europe Polio Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Polio Vaccine by Country
8.1.1 Middle East & Africa Polio Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Polio Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Polio Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Polio Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Polio Vaccine
10.3 Manufacturing Process Analysis of Polio Vaccine
10.4 Industry Chain Structure of Polio Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Polio Vaccine Distributors
11.3 Polio Vaccine Customer
12 WORLD FORECAST REVIEW FOR POLIO VACCINE BY GEOGRAPHIC REGION
12.1 Global Polio Vaccine Market Size Forecast by Region
12.1.1 Global Polio Vaccine Forecast by Region (2027-2032)
12.1.2 Global Polio Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Polio Vaccine Forecast by Type (2027-2032)
12.7 Global Polio Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Polio Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Polio Vaccine Product Portfolios and Specifications
13.2.3 GSK Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Polio Vaccine Product Portfolios and Specifications
13.3.3 Bibcol Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Polio Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Polio Vaccine Product Portfolios and Specifications
13.5.3 Tiantan Biological Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Polio Vaccine Product Portfolios and Specifications
13.6.3 IMBCA Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Polio Vaccine Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Polio Vaccine Product Portfolios and Specifications
13.8.3 Bio-Med Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Polio Vaccine Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Polio Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Polio Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Polio Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Polio Vaccine Segment by Type
2.2.1 Inactivated Polio Vaccine (IPV)
2.2.2 Oral Polio Vaccine (OPV)
2.2.3 Polio Vaccine Sales by Type
2.2.3.1 Global Polio Vaccine Sales Market Share by Type (2021-2026)
2.2.3.2 Global Polio Vaccine Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Polio Vaccine Sale Price by Type (2021-2026)
2.3 Polio Vaccine Segment by Virus Type
2.3.1 Monovalent
2.3.2 Bivalent
2.3.3 Trivalent
2.3.4 Polio Vaccine Sales by Virus Type
2.3.4.1 Global Polio Vaccine Sales Market Share by Virus Type (2021-2026)
2.3.4.2 Global Polio Vaccine Revenue and Market Share by Virus Type (2021-2026)
2.3.4.3 Global Polio Vaccine Sale Price by Virus Type (2021-2026)
2.4 Polio Vaccine Segment by Dosage Form
2.4.1 Oral Drops
2.4.2 Sugar Pill
2.4.3 Injection
2.4.4 Polio Vaccine Sales by Dosage Form
2.4.4.1 Global Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
2.4.4.2 Global Polio Vaccine Revenue and Market Share by Dosage Form (2021-2026)
2.4.4.3 Global Polio Vaccine Sale Price by Dosage Form (2021-2026)
2.5 Polio Vaccine Segment by Application
2.5.1 Public
2.5.2 Private
2.5.3 Polio Vaccine Sales by Application
2.5.3.1 Global Polio Vaccine Sale Market Share by Application (2021-2026)
2.5.3.2 Global Polio Vaccine Revenue and Market Share by Application (2021-2026)
2.5.3.3 Global Polio Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Polio Vaccine Breakdown Data by Company
3.1.1 Global Polio Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Polio Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Polio Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Polio Vaccine Revenue by Company (2021-2026)
3.2.2 Global Polio Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Polio Vaccine Sale Price by Company
3.4 Key Manufacturers Polio Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Polio Vaccine Product Location Distribution
3.4.2 Players Polio Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR POLIO VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Polio Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Polio Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Polio Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Polio Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Polio Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Polio Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Polio Vaccine Sales Growth
4.4 APAC Polio Vaccine Sales Growth
4.5 Europe Polio Vaccine Sales Growth
4.6 Middle East & Africa Polio Vaccine Sales Growth
5 AMERICAS
5.1 Americas Polio Vaccine Sales by Country
5.1.1 Americas Polio Vaccine Sales by Country (2021-2026)
5.1.2 Americas Polio Vaccine Revenue by Country (2021-2026)
5.2 Americas Polio Vaccine Sales by Type (2021-2026)
5.3 Americas Polio Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Polio Vaccine Sales by Region
6.1.1 APAC Polio Vaccine Sales by Region (2021-2026)
6.1.2 APAC Polio Vaccine Revenue by Region (2021-2026)
6.2 APAC Polio Vaccine Sales by Type (2021-2026)
6.3 APAC Polio Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Polio Vaccine by Country
7.1.1 Europe Polio Vaccine Sales by Country (2021-2026)
7.1.2 Europe Polio Vaccine Revenue by Country (2021-2026)
7.2 Europe Polio Vaccine Sales by Type (2021-2026)
7.3 Europe Polio Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Polio Vaccine by Country
8.1.1 Middle East & Africa Polio Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Polio Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Polio Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Polio Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Polio Vaccine
10.3 Manufacturing Process Analysis of Polio Vaccine
10.4 Industry Chain Structure of Polio Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Polio Vaccine Distributors
11.3 Polio Vaccine Customer
12 WORLD FORECAST REVIEW FOR POLIO VACCINE BY GEOGRAPHIC REGION
12.1 Global Polio Vaccine Market Size Forecast by Region
12.1.1 Global Polio Vaccine Forecast by Region (2027-2032)
12.1.2 Global Polio Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Polio Vaccine Forecast by Type (2027-2032)
12.7 Global Polio Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Polio Vaccine Product Portfolios and Specifications
13.1.3 Sanofi Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Polio Vaccine Product Portfolios and Specifications
13.2.3 GSK Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Bibcol
13.3.1 Bibcol Company Information
13.3.2 Bibcol Polio Vaccine Product Portfolios and Specifications
13.3.3 Bibcol Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Bibcol Main Business Overview
13.3.5 Bibcol Latest Developments
13.4 Serum Institute (Bilthoven Biologicals)
13.4.1 Serum Institute (Bilthoven Biologicals) Company Information
13.4.2 Serum Institute (Bilthoven Biologicals) Polio Vaccine Product Portfolios and Specifications
13.4.3 Serum Institute (Bilthoven Biologicals) Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Serum Institute (Bilthoven Biologicals) Main Business Overview
13.4.5 Serum Institute (Bilthoven Biologicals) Latest Developments
13.5 Tiantan Biological
13.5.1 Tiantan Biological Company Information
13.5.2 Tiantan Biological Polio Vaccine Product Portfolios and Specifications
13.5.3 Tiantan Biological Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Tiantan Biological Main Business Overview
13.5.5 Tiantan Biological Latest Developments
13.6 IMBCA
13.6.1 IMBCA Company Information
13.6.2 IMBCA Polio Vaccine Product Portfolios and Specifications
13.6.3 IMBCA Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 IMBCA Main Business Overview
13.6.5 IMBCA Latest Developments
13.7 Panacea Biotec Ltd
13.7.1 Panacea Biotec Ltd Company Information
13.7.2 Panacea Biotec Ltd Polio Vaccine Product Portfolios and Specifications
13.7.3 Panacea Biotec Ltd Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Panacea Biotec Ltd Main Business Overview
13.7.5 Panacea Biotec Ltd Latest Developments
13.8 Bio-Med
13.8.1 Bio-Med Company Information
13.8.2 Bio-Med Polio Vaccine Product Portfolios and Specifications
13.8.3 Bio-Med Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bio-Med Main Business Overview
13.8.5 Bio-Med Latest Developments
13.9 Halfkin Bio-Pharmaceuticals
13.9.1 Halfkin Bio-Pharmaceuticals Company Information
13.9.2 Halfkin Bio-Pharmaceuticals Polio Vaccine Product Portfolios and Specifications
13.9.3 Halfkin Bio-Pharmaceuticals Polio Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.9.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Polio Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Polio Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inactivated Polio Vaccine (IPV)
Table 4. Major Players of Oral Polio Vaccine (OPV)
Table 5. Global Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 6. Global Polio Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Polio Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Polio Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Polio Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Polio Vaccine Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Polio Vaccine Sales Market Share by Virus Type (2021-2026)
Table 15. Global Polio Vaccine Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Polio Vaccine Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Major Players of Injection
Table 21. Global Polio Vaccine Sales by Dosage Form (2021-2026) & (K Dose)
Table 22. Global Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
Table 23. Global Polio Vaccine Revenue by Dosage Form (2021-2026) & ($ million)
Table 24. Global Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Table 25. Global Polio Vaccine Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 26. Global Polio Vaccine Sale by Application (2021-2026) & (K Dose)
Table 27. Global Polio Vaccine Sale Market Share by Application (2021-2026)
Table 28. Global Polio Vaccine Revenue by Application (2021-2026) & ($ million)
Table 29. Global Polio Vaccine Revenue Market Share by Application (2021-2026)
Table 30. Global Polio Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Polio Vaccine Sales by Company (2021-2026) & (K Dose)
Table 32. Global Polio Vaccine Sales Market Share by Company (2021-2026)
Table 33. Global Polio Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Polio Vaccine Revenue Market Share by Company (2021-2026)
Table 35. Global Polio Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Polio Vaccine Producing Area Distribution and Sales Area
Table 37. Players Polio Vaccine Products Offered
Table 38. Polio Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Polio Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global Polio Vaccine Sales Market Share Geographic Region (2021-2026)
Table 43. Global Polio Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Polio Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Polio Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global Polio Vaccine Sales Market Share by Country/Region (2021-2026)
Table 47. Global Polio Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Polio Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 50. Americas Polio Vaccine Sales Market Share by Country (2021-2026)
Table 51. Americas Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 53. Americas Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 54. APAC Polio Vaccine Sales by Region (2021-2026) & (K Dose)
Table 55. APAC Polio Vaccine Sales Market Share by Region (2021-2026)
Table 56. APAC Polio Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 58. APAC Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 59. Europe Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 60. Europe Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 62. Europe Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa Polio Vaccine Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of Polio Vaccine
Table 68. Key Market Challenges & Risks of Polio Vaccine
Table 69. Key Industry Trends of Polio Vaccine
Table 70. Polio Vaccine Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Polio Vaccine Distributors List
Table 73. Polio Vaccine Customer List
Table 74. Global Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global Polio Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas Polio Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC Polio Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Polio Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global Polio Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Polio Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global Polio Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Sanofi Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Polio Vaccine Product Portfolios and Specifications
Table 90. Sanofi Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. GSK Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK Polio Vaccine Product Portfolios and Specifications
Table 95. GSK Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Bibcol Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Bibcol Polio Vaccine Product Portfolios and Specifications
Table 100. Bibcol Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Bibcol Main Business
Table 102. Bibcol Latest Developments
Table 103. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Serum?Institute?(Bilthoven?Biologicals) Polio Vaccine Product Portfolios and Specifications
Table 105. Serum?Institute?(Bilthoven?Biologicals) Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 107. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 108. Tiantan Biological Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Tiantan Biological Polio Vaccine Product Portfolios and Specifications
Table 110. Tiantan Biological Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Tiantan Biological Main Business
Table 112. Tiantan Biological Latest Developments
Table 113. IMBCA Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. IMBCA Polio Vaccine Product Portfolios and Specifications
Table 115. IMBCA Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. IMBCA Main Business
Table 117. IMBCA Latest Developments
Table 118. Panacea Biotec Ltd Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Panacea Biotec Ltd Polio Vaccine Product Portfolios and Specifications
Table 120. Panacea Biotec Ltd Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Panacea Biotec Ltd Main Business
Table 122. Panacea Biotec Ltd Latest Developments
Table 123. Bio-Med Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Bio-Med Polio Vaccine Product Portfolios and Specifications
Table 125. Bio-Med Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Bio-Med Main Business
Table 127. Bio-Med Latest Developments
Table 128. Halfkin Bio-Pharmaceuticals Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Halfkin Bio-Pharmaceuticals Polio Vaccine Product Portfolios and Specifications
Table 130. Halfkin Bio-Pharmaceuticals Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Halfkin Bio-Pharmaceuticals Main Business
Table 132. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Polio Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Polio Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Inactivated Polio Vaccine (IPV)
Table 4. Major Players of Oral Polio Vaccine (OPV)
Table 5. Global Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 6. Global Polio Vaccine Sales Market Share by Type (2021-2026)
Table 7. Global Polio Vaccine Revenue by Type (2021-2026) & ($ million)
Table 8. Global Polio Vaccine Revenue Market Share by Type (2021-2026)
Table 9. Global Polio Vaccine Sale Price by Type (2021-2026) & (US$/Dose)
Table 10. Major Players of Monovalent
Table 11. Major Players of Bivalent
Table 12. Major Players of Trivalent
Table 13. Global Polio Vaccine Sales by Virus Type (2021-2026) & (K Dose)
Table 14. Global Polio Vaccine Sales Market Share by Virus Type (2021-2026)
Table 15. Global Polio Vaccine Revenue by Virus Type (2021-2026) & ($ million)
Table 16. Global Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Table 17. Global Polio Vaccine Sale Price by Virus Type (2021-2026) & (US$/Dose)
Table 18. Major Players of Oral Drops
Table 19. Major Players of Sugar Pill
Table 20. Major Players of Injection
Table 21. Global Polio Vaccine Sales by Dosage Form (2021-2026) & (K Dose)
Table 22. Global Polio Vaccine Sales Market Share by Dosage Form (2021-2026)
Table 23. Global Polio Vaccine Revenue by Dosage Form (2021-2026) & ($ million)
Table 24. Global Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Table 25. Global Polio Vaccine Sale Price by Dosage Form (2021-2026) & (US$/Dose)
Table 26. Global Polio Vaccine Sale by Application (2021-2026) & (K Dose)
Table 27. Global Polio Vaccine Sale Market Share by Application (2021-2026)
Table 28. Global Polio Vaccine Revenue by Application (2021-2026) & ($ million)
Table 29. Global Polio Vaccine Revenue Market Share by Application (2021-2026)
Table 30. Global Polio Vaccine Sale Price by Application (2021-2026) & (US$/Dose)
Table 31. Global Polio Vaccine Sales by Company (2021-2026) & (K Dose)
Table 32. Global Polio Vaccine Sales Market Share by Company (2021-2026)
Table 33. Global Polio Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Polio Vaccine Revenue Market Share by Company (2021-2026)
Table 35. Global Polio Vaccine Sale Price by Company (2021-2026) & (US$/Dose)
Table 36. Key Manufacturers Polio Vaccine Producing Area Distribution and Sales Area
Table 37. Players Polio Vaccine Products Offered
Table 38. Polio Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Polio Vaccine Sales by Geographic Region (2021-2026) & (K Dose)
Table 42. Global Polio Vaccine Sales Market Share Geographic Region (2021-2026)
Table 43. Global Polio Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Polio Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Polio Vaccine Sales by Country/Region (2021-2026) & (K Dose)
Table 46. Global Polio Vaccine Sales Market Share by Country/Region (2021-2026)
Table 47. Global Polio Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Polio Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 50. Americas Polio Vaccine Sales Market Share by Country (2021-2026)
Table 51. Americas Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 53. Americas Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 54. APAC Polio Vaccine Sales by Region (2021-2026) & (K Dose)
Table 55. APAC Polio Vaccine Sales Market Share by Region (2021-2026)
Table 56. APAC Polio Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 58. APAC Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 59. Europe Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 60. Europe Polio Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 62. Europe Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 63. Middle East & Africa Polio Vaccine Sales by Country (2021-2026) & (K Dose)
Table 64. Middle East & Africa Polio Vaccine Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Polio Vaccine Sales by Type (2021-2026) & (K Dose)
Table 66. Middle East & Africa Polio Vaccine Sales by Application (2021-2026) & (K Dose)
Table 67. Key Market Drivers & Growth Opportunities of Polio Vaccine
Table 68. Key Market Challenges & Risks of Polio Vaccine
Table 69. Key Industry Trends of Polio Vaccine
Table 70. Polio Vaccine Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Polio Vaccine Distributors List
Table 73. Polio Vaccine Customer List
Table 74. Global Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 75. Global Polio Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 77. Americas Polio Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Polio Vaccine Sales Forecast by Region (2027-2032) & (K Dose)
Table 79. APAC Polio Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 81. Europe Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Polio Vaccine Sales Forecast by Country (2027-2032) & (K Dose)
Table 83. Middle East & Africa Polio Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Polio Vaccine Sales Forecast by Type (2027-2032) & (K Dose)
Table 85. Global Polio Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Polio Vaccine Sales Forecast by Application (2027-2032) & (K Dose)
Table 87. Global Polio Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. Sanofi Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 89. Sanofi Polio Vaccine Product Portfolios and Specifications
Table 90. Sanofi Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 91. Sanofi Main Business
Table 92. Sanofi Latest Developments
Table 93. GSK Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 94. GSK Polio Vaccine Product Portfolios and Specifications
Table 95. GSK Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 96. GSK Main Business
Table 97. GSK Latest Developments
Table 98. Bibcol Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 99. Bibcol Polio Vaccine Product Portfolios and Specifications
Table 100. Bibcol Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 101. Bibcol Main Business
Table 102. Bibcol Latest Developments
Table 103. Serum?Institute?(Bilthoven?Biologicals) Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 104. Serum?Institute?(Bilthoven?Biologicals) Polio Vaccine Product Portfolios and Specifications
Table 105. Serum?Institute?(Bilthoven?Biologicals) Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 106. Serum?Institute?(Bilthoven?Biologicals) Main Business
Table 107. Serum?Institute?(Bilthoven?Biologicals) Latest Developments
Table 108. Tiantan Biological Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 109. Tiantan Biological Polio Vaccine Product Portfolios and Specifications
Table 110. Tiantan Biological Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 111. Tiantan Biological Main Business
Table 112. Tiantan Biological Latest Developments
Table 113. IMBCA Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 114. IMBCA Polio Vaccine Product Portfolios and Specifications
Table 115. IMBCA Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 116. IMBCA Main Business
Table 117. IMBCA Latest Developments
Table 118. Panacea Biotec Ltd Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 119. Panacea Biotec Ltd Polio Vaccine Product Portfolios and Specifications
Table 120. Panacea Biotec Ltd Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 121. Panacea Biotec Ltd Main Business
Table 122. Panacea Biotec Ltd Latest Developments
Table 123. Bio-Med Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 124. Bio-Med Polio Vaccine Product Portfolios and Specifications
Table 125. Bio-Med Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 126. Bio-Med Main Business
Table 127. Bio-Med Latest Developments
Table 128. Halfkin Bio-Pharmaceuticals Basic Information, Polio Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 129. Halfkin Bio-Pharmaceuticals Polio Vaccine Product Portfolios and Specifications
Table 130. Halfkin Bio-Pharmaceuticals Polio Vaccine Sales (K Dose), Revenue ($ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 131. Halfkin Bio-Pharmaceuticals Main Business
Table 132. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Polio Vaccine
Figure 2. Polio Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Polio Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Polio Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Polio Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Polio Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Polio Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inactivated Polio Vaccine (IPV)
Figure 12. Product Picture of Oral Polio Vaccine (OPV)
Figure 13. Global Polio Vaccine Sales Market Share by Type in 2026
Figure 14. Global Polio Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Polio Vaccine Sales Market Share by Virus Type in 2026
Figure 19. Global Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Product Picture of Injection
Figure 23. Global Polio Vaccine Sales Market Share by Dosage Form in 2026
Figure 24. Global Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Figure 25. Polio Vaccine Consumed in Public
Figure 26. Global Polio Vaccine Market: Public (2021-2026) & (K Dose)
Figure 27. Polio Vaccine Consumed in Private
Figure 28. Global Polio Vaccine Market: Private (2021-2026) & (K Dose)
Figure 29. Global Polio Vaccine Sale Market Share by Application (2025)
Figure 30. Global Polio Vaccine Revenue Market Share by Application in 2025
Figure 31. Polio Vaccine Sales by Company in 2025 (K Dose)
Figure 32. Global Polio Vaccine Sales Market Share by Company in 2025
Figure 33. Polio Vaccine Revenue by Company in 2025 ($ millions)
Figure 34. Global Polio Vaccine Revenue Market Share by Company in 2025
Figure 35. Global Polio Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Polio Vaccine Revenue Market Share by Geographic Region in 2025
Figure 37. Americas Polio Vaccine Sales 2021-2026 (K Dose)
Figure 38. Americas Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 39. APAC Polio Vaccine Sales 2021-2026 (K Dose)
Figure 40. APAC Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 41. Europe Polio Vaccine Sales 2021-2026 (K Dose)
Figure 42. Europe Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Polio Vaccine Sales 2021-2026 (K Dose)
Figure 44. Middle East & Africa Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 45. Americas Polio Vaccine Sales Market Share by Country in 2025
Figure 46. Americas Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 47. Americas Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 48. Americas Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 49. United States Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Polio Vaccine Sales Market Share by Region in 2025
Figure 54. APAC Polio Vaccine Revenue Market Share by Region (2021-2026)
Figure 55. APAC Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 56. APAC Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 57. China Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. India Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Polio Vaccine Sales Market Share by Country in 2025
Figure 65. Europe Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 66. Europe Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Europe Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Germany Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. France Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Polio Vaccine Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 76. Egypt Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Polio Vaccine in 2026
Figure 82. Manufacturing Process Analysis of Polio Vaccine
Figure 83. Industry Chain Structure of Polio Vaccine
Figure 84. Channels of Distribution
Figure 85. Global Polio Vaccine Sales Market Forecast by Region (2027-2032)
Figure 86. Global Polio Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Polio Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Polio Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Polio Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Polio Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Polio Vaccine
Figure 2. Polio Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Polio Vaccine Sales Growth Rate 2021-2032 (K Dose)
Figure 7. Global Polio Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Polio Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Polio Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Polio Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Inactivated Polio Vaccine (IPV)
Figure 12. Product Picture of Oral Polio Vaccine (OPV)
Figure 13. Global Polio Vaccine Sales Market Share by Type in 2026
Figure 14. Global Polio Vaccine Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of Monovalent
Figure 16. Product Picture of Bivalent
Figure 17. Product Picture of Trivalent
Figure 18. Global Polio Vaccine Sales Market Share by Virus Type in 2026
Figure 19. Global Polio Vaccine Revenue Market Share by Virus Type (2021-2026)
Figure 20. Product Picture of Oral Drops
Figure 21. Product Picture of Sugar Pill
Figure 22. Product Picture of Injection
Figure 23. Global Polio Vaccine Sales Market Share by Dosage Form in 2026
Figure 24. Global Polio Vaccine Revenue Market Share by Dosage Form (2021-2026)
Figure 25. Polio Vaccine Consumed in Public
Figure 26. Global Polio Vaccine Market: Public (2021-2026) & (K Dose)
Figure 27. Polio Vaccine Consumed in Private
Figure 28. Global Polio Vaccine Market: Private (2021-2026) & (K Dose)
Figure 29. Global Polio Vaccine Sale Market Share by Application (2025)
Figure 30. Global Polio Vaccine Revenue Market Share by Application in 2025
Figure 31. Polio Vaccine Sales by Company in 2025 (K Dose)
Figure 32. Global Polio Vaccine Sales Market Share by Company in 2025
Figure 33. Polio Vaccine Revenue by Company in 2025 ($ millions)
Figure 34. Global Polio Vaccine Revenue Market Share by Company in 2025
Figure 35. Global Polio Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Polio Vaccine Revenue Market Share by Geographic Region in 2025
Figure 37. Americas Polio Vaccine Sales 2021-2026 (K Dose)
Figure 38. Americas Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 39. APAC Polio Vaccine Sales 2021-2026 (K Dose)
Figure 40. APAC Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 41. Europe Polio Vaccine Sales 2021-2026 (K Dose)
Figure 42. Europe Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Polio Vaccine Sales 2021-2026 (K Dose)
Figure 44. Middle East & Africa Polio Vaccine Revenue 2021-2026 ($ millions)
Figure 45. Americas Polio Vaccine Sales Market Share by Country in 2025
Figure 46. Americas Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 47. Americas Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 48. Americas Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 49. United States Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Polio Vaccine Sales Market Share by Region in 2025
Figure 54. APAC Polio Vaccine Revenue Market Share by Region (2021-2026)
Figure 55. APAC Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 56. APAC Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 57. China Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. India Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Polio Vaccine Sales Market Share by Country in 2025
Figure 65. Europe Polio Vaccine Revenue Market Share by Country (2021-2026)
Figure 66. Europe Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Europe Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Germany Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. France Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Polio Vaccine Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Polio Vaccine Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Polio Vaccine Sales Market Share by Application (2021-2026)
Figure 76. Egypt Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Polio Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Polio Vaccine in 2026
Figure 82. Manufacturing Process Analysis of Polio Vaccine
Figure 83. Industry Chain Structure of Polio Vaccine
Figure 84. Channels of Distribution
Figure 85. Global Polio Vaccine Sales Market Forecast by Region (2027-2032)
Figure 86. Global Polio Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Polio Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Polio Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Polio Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Polio Vaccine Revenue Market Share Forecast by Application (2027-2032)
